Progyny Inc
$ 28.10
-6.98%
07 Aug - close price
- Market Cap 2,201,139,000 USD
- Current Price $ 28.10
- High / Low $ 29.25 / 25.09
- Stock P/E 39.03
- Book Value 5.66
- EPS 0.72
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 0.15 %
- 52 Week High 33.06
- 52 Week Low 16.10
About
Progyny, Inc., a benefits management company, specializes in fertility benefits and family development solutions for employers in the United States. The company is headquartered in New York, New York.
Analyst Target Price
$33.82
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-07 | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-12 | 2024-08-06 | 2024-05-09 | 2024-02-27 | 2023-11-07 |
| Reported EPS | 0.34 | 0.5 | 0.14 | 0.45 | 0.19 | 0.48 | 0.42 | 0.4 | 0.43 | 0.39 | 0.13 | 0.16 |
| Estimated EPS | 0.28 | 0.44 | 0.13 | 0.39 | 0.17 | 0.45 | 0.37 | 0.37 | 0.4 | 0.35 | 0.11 | 0.11 |
| Surprise | 0.06 | 0.06 | 0.01 | 0.06 | 0.02 | 0.03 | 0.05 | 0.03 | 0.03 | 0.04 | 0.02 | 0.05 |
| Surprise Percentage | 21.4286% | 13.6364% | 7.6923% | 15.3846% | 11.7647% | 6.6667% | 13.5135% | 8.1081% | 7.5% | 11.4286% | 18.1818% | 45.4545% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PGNY
2026-08-07 15:40:00
Progyny's stock initially dropped by 6% after its second-quarter earnings report, despite sales rising 5% and adjusted earnings per share increasing by 15%, both exceeding Wall Street expectations. The market reacted negatively to management's conservative Q3 revenue growth guidance of 7% to 11%. However, the company's solid Q2 performance, including expanding gross profit margins and the introduction of its new "Progyny Select" offering for smaller employers, suggests a positive long-term outlook, leading to a gradual recovery in the stock price.
2026-08-07 14:40:00
Progyny, Inc. announced that its CEO, Pete Anevski, will present at the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 3:30 p.m. ET. The presentation will be accessible via a live audiocast and replay on Progyny’s investor relations website. Progyny is a leading company in women's health and family building solutions, recognized for its comprehensive approach to improving health outcomes and reducing healthcare costs.
2026-08-07 14:40:00
Progyny, Inc. (Nasdaq: PGNY) announced that its CEO, Pete Anevski, will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA, on Tuesday, August 11, 2026, at 3:30 p.m. ET. Live audiocasts and replays of the webcasted session will be accessible via the Events and Presentations section of Progyny’s investor relations website. The presentation will offer insights into Progyny's role as a leader in women’s health and family building solutions.
2026-08-07 09:40:00
Progyny, Inc. has published its Q2 2026 earnings call presentation. The company reported EPS of $0.55, beating estimates by $0.03, and revenue of $350.51 million, surpassing expectations by $1.86 million, representing a 5.30% year-over-year increase. This article provides access to the slide deck presented during the earnings call.
2026-08-07 05:11:16
Progyny Inc (PGNY) reported record revenue, gross profit, and adjusted EBITDA for Q2 2026, with revenue increasing 5.3% year-over-year. The company provided full-year 2026 guidance, projecting revenue between $1.36 billion and $1.385 billion, and reaffirmed strong selling season momentum and client retention. Despite a slight downward adjustment in Q3 guidance due to summer seasonality, Progyny continues to generate strong cash flow and execute significant share repurchases.
2026-08-07 01:11:16
Progyny (Nasdaq: PGNY) reported Q2 2026 revenue of $350.5 million, a 5.3% year-over-year increase, and diluted EPS of $0.34, significantly up from $0.19 in Q2 2025. The company's profit growth outpaced revenue growth due to gross-margin expansion and lower stock-based compensation, despite a decline in quarterly operating cash flow. Management provided guidance for Q3 and full-year 2026, anticipating a seasonal slowdown in Q3 but strong selling-season momentum.
